Cooperative Agreement W81XWH2020032

The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $889,188 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new therapy for the early resuscitation of cardiac arrest patients. The proposed therapy involves the intravenous administration of oxygen-containing polymeric microbubbles (IVO2) that can rapidly restore oxygen levels without requiring...

This $704,795 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Baylor College of Medicine supports the development of a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The project aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 and encapsulate them in alginate-based...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in facilitating alveolar epithelial regeneration following lung injury, with a focus on the signaling molecule R-spondin3. The research aims to: 1) examine how aerocyte-derived R-spondin3 regulates lung...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,160,157 Project Grant to Liberandum Technologies, Inc. to develop and test a bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in patients with acute respiratory distress syndrome (ARDS). The key goals of this Phase I SBIR project are to perform computational fluid dynamics (CFD) analysis, develop a...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to study the role of plasma cells in chronic rejection after lung transplantation. The $2,241,717 grant, awarded on September 2, 2024, will be performed by the University of Pittsburgh over a 4-year period ending on May 31, 2028. The key objectives of this research are to: 1) Provide a comprehensive analysis of B cell and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $229,971 to the University of North Carolina at Chapel Hill (UNC-CH) to develop and test novel hydrogel patches to prevent air leaks after lung surgery. The patches are designed to be ultra-elastic and instantly adhesive, allowing them to stretch with lung movement and seal perforations in lung tissue. Through in...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $842,408 to Inspire RX LLC to develop and evaluate the Aerosolve Biohelmet. The Aerosolve Biohelmet is a personal negative pressure device designed to safely transport and treat patients with highly transmissible respiratory illnesses, including COVID-19, influenza, tuberculosis, and measles. The project aims to refine the Biohelmet...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $124,536 to The General Hospital Corporation (Massachusetts General Hospital) to study the protective role of B cells in hyperoxic lung injury. The key objectives are to characterize the dynamics of B cell responses during hyperoxia exposure, examine the protective impacts of B cell supplementation, and investigate mechanistic...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,099 to the Massachusetts Institute of Technology (MIT) to conduct research on treatment strategies for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered under this grant include: Utilizing "target trial emulation" and advanced causal inference methods to analyze observational data...